ArticleBMC infectious diseases2025
Treatment patterns of empirical antibiotic therapies for critically ill patients with sepsis: a cross-sectional study in Vietnam.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA systematic description of patterns of empirical antibiotic therapies (EAT) and the factors driving these in critically ill patients with sepsis is lacking in resource-limited settings. We aimed to address this knowledge gap by exploring the EAT patterns and risk factors for deviations from the guidelines in EAT in a Vietnamese hospital.
methodsWe conducted a simple random-sampling cross-sectional study at the intensive care unit (ICU) using medical records of critically ill patients with sepsis. The outcomes were guideline-compliant and guideline-deviant EAT (GcEAT and GdEAT). GcEAT was full compliance (choice and dosage) with local protocol for sepsis management, while GdEAT was any treatment that was not GcEAT. We used descriptive statistics to present data. Risk factors for GdEAT were reported with adjusted odds ratio, 95% confidence interval (OR and 95% CI; using multivariable logistic regression) and E-value (for factors with significant associations).
resultsAmong 93 medical records included for analysis (median age of 68, 41.9% being male, 24.7% being overweight-to-obese). Initiation through the concurrent administration of three antibiotic agents was reported in 37.6% of all cases (96.8% with pseudomonal coverage, 91.4% with anaerobic coverage, 34.4% with MRSA coverage, 49.5% with enterococcal coverage). GcEAT was detected in 62 records (66.7%, 95% CI 56.6% to 75.4%), while GdEAT was in 31 records (33.3%, 95% CI 24.6% to 43.4%). The specific patterns in the GdEAT group were: (1) broader/narrower antibacterial coverage (87.1%) and overlapping targets (12.9%) (for choice of EAT), (2) higher/lower doses (45.2%), longer/shorter dosing intervals (38.7%), and without therapeutic drug monitoring (16.1%) (for dosage of EAT). Acute kidney injury before ICU admission was identified as a potential risk factor for GdEAT (adjusted OR 3.41, 95% CI 1.16 to 10.01; E-value 3.10, lower bound of CI 1.37), which was mainly driven by deviations in the dosage of EAT (adjusted OR 3.45, 95% 1.18 to 10.08; E-value 3.12, lower bound of CI 1.39).
conclusionGdEAT was moderately prevalent in sepsis management of critically ill patients at a Vietnamese healthcare setting, primarily due to deviations in choice and dosage of the EAT. Further research and updated guidelines should address the optimal EAT in patients with acute kidney injury to avoid unstandardised deviations and noncompliances with antimicrobial protocols. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.